Floatz logo

ANASTROZOLE

Female Breast Carcinoma

Ahon Pharmaceutical Co., Ltd.Small moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Female Breast Carcinoma cohort.

Asset / SponsorPhaseRating
PROPOFOL
Tata Memorial Centre
Phase 4BB
Sevoflurane
Tata Memorial Centre
Phase 4BB
Goserelin
Ahon Pharmaceutical Co., Ltd.
Phase 3BB
TOREMIFENE
Peking Union Medical College Hospital
Phase 4BB
FULVESTRANT
Ahon Pharmaceutical Co., Ltd.
Phase 3BB

View all 21 →

Same molecule, other indications

ANASTROZOLE is also rated in:

hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
invasive breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →